Dispensed: Change at the FDA, insurance startup financials for 2018, and the first new depression drug in 35 years


Hoo boy, it was a week. As I started to pull together the stories that kept us busy this week, it seemed like every day had another breaking development: from the authorized generic insulin, to FDA Commissioner Scott Gottlieb’s imminent departure, to the approval of a new depression drug, and a name for the JPMorgan-Amazon Berkshire Hathaway-Amazon joint health venture (Haven!). Meanwhile, the Wall Street Journal had this fascinating update from Martin Shkreli’s

Continue reading...